Navigation Links
Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
Date:7/13/2009

SOUTH SAN FRANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq: BIIB) for the selection of a Raf kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting IND-enabling GLP preclinical work with the Raf kinase development candidate.

"While our internal efforts are focused on the successful development of voreloxin, we are extremely pleased by the continued progress being made by Biogen Idec to advance a Raf kinase inhibitor toward the clinic," said Daniel Swisher, Sunesis' Chief Executive Officer.

In August 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The research term of this collaboration ended in June of 2008. Sunesis retains an option to participate in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

    Investor Contact:                           Media Contact:
    Sunesis Pharmaceuticals, Inc.               Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt                              Dan Weinseimer
    650-266-3717                                650-266-3739


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
2. Sunesis Reports Financial Results for the First Quarter 2009
3. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
4. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
8. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide ... a distribution partnership with Byers Scientific & Manufacturing , a leading designer, ... the agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific ...
(Date:1/24/2017)... ... ... This Saturday, January 28, the BCFA presents more than 20 local performances including Chinese ... Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide a ... Chinese games, crafts & more. Festivities begin at 11:00 am and end at 2:30 ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the ... everyone and particularly good news for prostate cancer patients: incidents of cancer is down ... to the report the cancer death rate has dropped from its peak of 215.1 ...
(Date:1/24/2017)... ... January 24, 2017 , ... Today, Taza ... latest award-winning bottles, designed specifically to optimize the drinking experience for K-Cup coffee, ... renowned for introducing the world’s first untouched bottled water purposed exclusively for creating ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing ... like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. ... Dr. Judith Coats and Dr. David Coats. In September of 1983, they flew ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)...  In a major study released this weekend ... 1 ( http://www.multivu.com/players/English/7899551-nephrocheck-test-acute-kidney-injury-outcomes/ ), Astute ... identified patients at high risk of Acute Kidney ... randomized control trial led by Alexander Zarbock ... institution,s standard of care or a treatment per ...
(Date:1/24/2017)... Jan. 24, 2017 When tragedy strikes, victims often can,t ... what conditions they have, and who back home is wondering about ... ones informed about the safety of their family and friends, while ... victims in times of crisis. ... If you find yourself or your family in one ...
(Date:1/24/2017)... 2017 Market Research Future has a half cooked research ... market for Plastic Surgery & Integumentary System is growing rapidly and ... forecasted period. Market Highlights ... Global Plastic Surgery & Integumentary System Market has ... market will reach high growth figures and thriving in the coming ...
Breaking Medicine Technology: